AAPL vs ABT Stock Comparison

Scores Breakdown

Metric	AAPL	ABT
📈 Growth	18/30	22/30
💰 Profitability	16/20	17/20
🏦 Financial Health	18/20	15/20
💵 Valuation	14/20	12/20
⚠️ Risk (lower is better)	4/10	4/10
Overall Score	72/100	72/100

Side-by-Side Summaries

AAPL Analysis	ABT Analysis
📈 Growth & Financial Trajectory Over eight quarters, Apple shows revenue volatility but an overall uptick: from approximately Revenues 94.93B in 2024 Q3 to about 111.18B in 2026 Q2, a gain of ~16B. Net income rose from about 21.45B to ~29.58B, though quarterly results swing with mid-cycle peaks (e.g., 2025 Q1) and pullbacks (2025 Q2) that temper a steady climb. 💰 Margins & Cash Flow Gross margin remains robust, typically in the high-40s percent range. Operating leverage is evident as operating income stays positive even when revenues pause. Cash flow shows resilience: Net Cash Flow From Operating Activities is generally positive across quarters, with seasonal peaks; investing cash outflows are typical, while financing activity cash flows vary by quarter. 🛡️ Balance Sheet & Liquidity Assets exceed liabilities by a wide margin, with sizable current assets and a strong equity base. Debt levels are manageable relative to cash generation, and the balance sheet demonstrates liquidity headroom to support ongoing capex and buybacks. ⚠️ Key Drivers & Risks Drivers: Premium hardware and Services expansion; margin resilience amid product cycles Risks: Valuation sensitivity to growth prospects; cyclicality and FX/macro headwinds	📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

AAPL Analysis

ABT Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Apple shows revenue volatility but an overall uptick: from approximately Revenues 94.93B in 2024 Q3 to about 111.18B in 2026 Q2, a gain of ~16B. Net income rose from about 21.45B to ~29.58B, though quarterly results swing with mid-cycle peaks (e.g., 2025 Q1) and pullbacks (2025 Q2) that temper a steady climb.

💰 Margins & Cash Flow

Gross margin remains robust, typically in the high-40s percent range. Operating leverage is evident as operating income stays positive even when revenues pause. Cash flow shows resilience: Net Cash Flow From Operating Activities is generally positive across quarters, with seasonal peaks; investing cash outflows are typical, while financing activity cash flows vary by quarter.

🛡️ Balance Sheet & Liquidity

Assets exceed liabilities by a wide margin, with sizable current assets and a strong equity base. Debt levels are manageable relative to cash generation, and the balance sheet demonstrates liquidity headroom to support ongoing capex and buybacks.

⚠️ Key Drivers & Risks

Drivers: Premium hardware and Services expansion; margin resilience amid product cycles
Risks: Valuation sensitivity to growth prospects; cyclicality and FX/macro headwinds

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

Similar Companies

AMZN Score: 75 BRK.B Score: 60 DIS Score: 69 GOOG Score: 78 GOOGL Score: 78 META Score: 79 MSFT Score: 87 NFLX Score: 78 NVDA Score: 85 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"